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Objectives. The purpose of these studies was to understand the influence of cosolvent and surfactant contributions to particle
size distributions emitted from solution metered dose inhalers (pMDIs) based on the propellant HFA 227. Methods. Two sets of
formulations were prepared: (a) pMDIs-HFA 227 containing cosolvent (5–15% w/w ethanol) with constant surfactant (pluronic)
concentration and (b) pMDIs-HFA 227 containing surfactant (0–5.45% w/w pluronic) with constant cosolvent concentration.
Particle size distributions emitted from these pMDIs were analyzed using aerodynamic characterization (inertial impaction) and
laser diffraction methods. Results. Both cosolvent and surfactant concentrations were positively correlated with median particle
sizes; that is, drug particle size increased with increasing ethanol and pluronic concentrations. However, evaluation of particle size
distributions showed that cosolvent caused reduction in the fine particle mode magnitude while the surfactant caused a shift in
the mode position.These findings highlight the different mechanisms by which these components influence droplet formation and
demonstrate the ability to utilize the different effects in formulations of pMDI-HFA 227 for independentlymodulating particle sizes
in the respirable region. Conclusion. Potentially, the formulation design window generated using these excipients in combination
could be used to match the particle size output of reformulated products to preexisting pMDI products.
1. Introduction
Pressurized metered dose inhalers (pMDIs) have found fre-
quent application in the delivery of therapeutics for treatment
of pulmonary diseases, such as asthma and chronic obstruc-
tive pulmonary disease [1]. They are compact and have the
potential to deliver a wide range of doses and drugs [2]. In
general, pMDI formulations comprise a therapeutic material,
a propellant, cosolvents, and surfactants toprevent drug-
aerosol coagulation and lubricate moving parts of the meter-
ing valve.
Historically, pMDIs propellants were ozone-depleting
chlorofluorocarbons (CFCs) [3]. This prompted the well-
documented search for more environmentally friendly alter-
natives, such as the biocompatible, nonozone depleting
hydrofluoroalkanes (tetrafluoroethane [HFA-134] and hep-
tafluoropropane [HFA 227]) [4, 5]. Many of the presently
marketed pMDIs contain HFA-134, as it was the first propel-
lant to have full term toxicity testing [6]. However, despite
some similarities in densities and vapor pressures, the physic-
ochemical properties of HFAs and CFCs differ significantly
[7, 8], leading to incompatibilities with traditional excipients,
canister components, and valve elastomers. This has led to
difficulties for reformulators trying tomatch the performance
of newer generation formulations to those they are attempt-
ing to replace. The particle size distribution of inhalation
aerosols is a critical parameter that needs to be carefully con-
trolled since it determines where the aerosol will deposit in
the respiratory tract and is closely linked to the efficacy aswell
as the side effects of the deliveredmedication as evidenced by
the CFC to HFA transition [9, 10]. Furthermore, the particle
size distribution of a pMDI aerosol depends on the physic-
ochemical properties of the formulation [11]. Thus, refor-
mulating pMDIs from CFCs to HFAs has been problematic,
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particularly when attempts have beenmade tomatch the per-
formance of these two systems (aerosol output equivalence).
This approach of reformulating pMDIs based on bioequiva-
lency to the CFC pMDIs they have replaced was adopted by
most companies involved in the transition fromCFC toHFAs
[8]. To achieve equivalence, there are two general strategies
which can be used tomodulate aerosol output and lung depo-
sition of pMDIs; the first is altering the formulation param-
eters such as propellant and excipients which we have previ-
ously reviewed [8, 11]. Secondly, device design can be changed
rationally to induce changes in aerosol output as we have
previously shown for actuator nozzle dimensions [12, 13].
Part of the issue for matching deposition profiles of
different products has been the difficulty in matching aerosol
output beyond the mass median aerodynamic diameters and
other composite measures such as fine particle fraction or
respirable fractions. Indeed, it has been reported that HFA-
134 solution formulations displayed multimodal particle size
distributions. In these studies, varying cosolvent concen-
trations in HFA-134/ethanol pMDIs influenced particle size
distribution but did not cause particle size modes to shift
[5, 11]. This is problematic for formulators wishing to show
equivalence with monomodal aerosols since changes in par-
ticle size output modulated by use of cosolvents alone will be
insufficient to obtain a match of aerosol deposition profiles.
In the current studies, we show that by controlling both
cosolvent and surfactant concentrations, the aerosol particle
size distributions can be modulated both along the 𝑥 and 𝑦
axes; that is, HFA 227 solution formulations can be tuned
within a performance space. Specifically, the aim of these
studies was to investigate the influence of changing the con-
centrations of a model surfactant (Pluronic L81) and ethanol
on the emitted particle size distribution and in vitro aerosol
deposition studies.
2. Materials and Methods
2.1. Materials. The propellant 1,1,1,2,3,3,3-heptafluoropro-
pane (HFA 227) was provided as a gift from Solvay Fluorides
Inc. (Houston, TX, USA). Fluorescein sodium (fluorescein
Na) was purchased from Sigma-Aldrich (St. Louis, MO,
USA). Ethanol (EtOH) (HPLC grade) and methanol (HPLC
grade) were purchased from VWR (West Chester, PA, USA).
Aluminium aerosol canisters andmetered dose valves (25𝜇L)
were provided as a gift from Valois Pharmaceuticals (Marly-
le-Roi, France). Pluronic L81 was a gift from BASF Corp
(Parsippany, NJ, USA).
2.2. Preparation of PressurisedMeteredDose Inhalers (pMDIs).
A series of formulations were prepared (Table 1) containing
various amounts by weight of Pluronic L81 and HFA 227
propellant with constant ethanol concentration (% w/w) and
fluorescein Na drug mass (% w/w), as a model drug. Table 2
represents formulations consisting of different ethanol con-
centrations (% w/w) but maintaining constant Pluronic
L81 (% w/w) and fluorescein Na (% w/w) concentrations.
Significant preformulation, solubility, and stability studies
Table 1: Composition of HFA 227 formulations maintaining con-
stant fluorescein Na and ethanol concentration (𝑛 = 3).
Formulation Pluronic L81(% w/w)
Ethanol
(% w/w)
Fluorescein Na
(% w/w)
1.22% w/w Pluronic L81 1.22 13.3 0.04
5.45% w/w Pluronic L81 5.45 13.4 0.04
0% w/w Pluronic L81 0∗ 13.3 0.04
∗Formulation 0% w/w Pluronic L81 contained 1.22% w/w of deionized water
as a replacement for Pluronic L81 to maintain mass balance.
Table 2: Composition of HFA 227 formulations maintaining con-
stant Pluronic L81 and fluorescein Na concentrations (𝑛 = 3).
Formulation Pluronic L81(% w/w)
Ethanol
(% w/w)
Fluorescein Na
(% w/w)
5% w/w EtOH 5 5 0.04
10% w/w EtOH 5 10 0.04
13% w/w EtOH 5 13 0.04
15% w/w EtOH 5 15 0.04
were performed to ensure compatibility of the model drug,
excipients, and propellants (data not shown).
Aliquots of Pluronic L81, ethanol, and fluorescein Na,
as represented in Tables 1 and 2, were added by weight to
aluminium aerosol canisters. Metered dose valves were then
crimped onto the canisters using a manual canister crimper
(Aero-Tech Laboratory Equipment Company, Worcester,
NY) and filled with the desired weight of HFA 227 propellant
using a pressure burette (Aero-Tech Laboratory Equipment
Company, Worcester, NY, USA). All canisters were equipped
with a 0.33 𝜇m actuator (Valois Pharmaceuticals, Marly-le-
Roi, France) and prepared on the same day as testing.
2.3. Particle Size Analysis of Drug (Fluorescein Na) Using Laser
Diffraction. Particle size characteristics of each of the formu-
lations were determined using a SympatecHelos laser diffrac-
tion instrument (Sympatec GmbH, Germany). The pMDI
was positioned at a set distance from the laser beam and at
a fixed height ensuring that the aerosol plume was projected
across the laser. This was achieved by placing the aerosol
device such that the actuator orifice was within the lens cut-
off distance and was aligned with the height of the laser path.
Particle size distribution was measured using four actuations
shaking the canister between actuations five times and
expressed as the volume median diameter (VMD) (𝑛 = 4).
2.4. Aerodynamic Particle Size Distributions of Drug (Flu-
orescein Na) Using the Next Generation Impactor (NGI).
Aerodynamic particle size distributions were determined
from cascade impaction studies using a Next Generation
Impactor (NGI) (MSP Corp, MN, USA) containing a United
States Pharmacopeia induction port and operated at a flow
rate of 30 L/min, precalibrated using a Gilmont Flowmeter
BaseModel F-4001 (Barnant Company, Barrington, IL,USA).
The metering valves were primed by discharging three shots
to waste. The pump was switched on 5 seconds prior to
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Table 3: Comparison of formulations with different concentrations
of Pluronic L81 (data represent mean ± SD, 𝑛 = 3).
Pluronic L81 Concentration (% w/w)
0 1.22 5.45
ED (𝜇g) 170.69 ± 21.85∗∗ 211.14 ± 9.63 215.14 ± 11.55
FPF (%) 49.63 ± 2.00 50.72 ± 0.69 33.20 ± 3.37∗
FPD (𝜇g) 84.61 ± 10.19 107.05 ± 3.53 71.17 ± 3.79#
MMAD (𝜇m) 1.56 ± 0.05$ 3.70 ± 0.08$ 5.93 ± 0.49$
GSD 3.22 ± 0.31 2.00 ± 0.05 1.78 ± 0.07
VMD (𝜇m) 7.07 ± 0.14 8.39 ± 0.11 11.04 ± 0.46∗
ED: emitted dose, MMAD: mass median aerodynamic diameter, FPF: fine
particle fraction, FPD: fine particle dose, and GSD: geometric standard
deviation. ∗∗𝑃 < 0.05 (ANOVA/Tukey’s) 0% w/w Pluronic L81 versus
1.22 and 5.45% w/w Pluronic L81, ∗𝑃 < 0.05 (ANOVA/Tukey’s) 5.45%
w/w Pluronic L81 versus 0 and 1.22% w/w Pluronic L81, #𝑃 < 0.05
(ANOVA/Tukey’s) 5.45% w/w Pluronic L81 versus 1.22% w/w Pluronic L81,
and $𝑃 < 0.05 comparing all formulations.
pMDI discharge, and pMDI was actuated ten times (𝑛 = 3).
The emitted dose (ED) was expressed as the total mass of
drug emitted from the inhaler. The fine particle fraction (%
FPF) (defined as the mass of drug deposited (𝑑ae ≤ 4.6 𝜇m)
was expressed as a percentage of the emitted dose and the
fine particle dose (FPD) was expressed as the mass of drug
deposited in the NGI (𝑑ae ≤ 4.6 𝜇m). Furthermore, inertial
impaction data was also subjected to log-probability analysis
to allow the derivation ofmassmedian aerodynamic diameter
(MMAD) and geometric standard deviation (GSD) for each
formulation [14].
2.5. Chemical Analysis. Fluorescein Na captured on the actu-
ator, induction port, and stages was extracted with methanol
(HPLC grade). The aerodynamic particle size distribution
was determined by analyzing each of the collected samples
for fluorescein Na content by HPLC using a Hitachi Elite
LaChrom (Hitachi, CA, USA) with UV detection at 490 nm
using a Kromasil C8 column (150mm × 4.6mm i.d., Col-
umn Engineering, CA, USA). The mobile phase consisted
of methanol : water (60 : 40) at a flow rate of 1.0mL/min,
injection volume 10 𝜇L, and quantification was by peak area
using a standard curve in the range 0–25𝜇g/mL.
2.6. Statistical Analysis. The formulations were compared
with each other by means of a one-way ANOVAwith Tukey’s
comparison test. The statistical significance level was set at
𝑃 ≤ 0.05.
3. Results
3.1. Effect of Surfactant Concentration on Particle Size Distri-
butions Emitted from HFA 227 pMDIs. Investigations looked
at the influence of altering surfactant levels in the HFA 227
pMDIs on aerosolization and particle size. Laser diffraction
data (Table 3) illustrated a direct correlation between increas-
ing surfactant concentration resulting in larger particle size
(VMD).
Thiswas further reflected in theMMADand emitted dose
data from cascade impaction studies. However, a significant
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Figure 1: Comparison of HFA 227 formulations with varying
concentrations of Pluronic L81 in terms of drug deposited in USP
throat of NGI maintaining constant concentration of fluorescein
Na and ethanol (data represent mean ± SD, 𝑛 = 3). ∗𝑃 < 0.05
(ANOVA/Tukey’s) 5.45% w/w Pluronic L81 versus 1.22 & 0% w/w
Pluronic L81.
decrease in FPD and FPF was observed as the surfactant
concentration was increased from 1.22% w/w to 5.45% w/w
(𝑃 < 0.05, ANOVA/Tukey’s). Similarly, USP induction port
deposition was positively correlated with surfactant concen-
trations, with 5.45% w/w Pluronic L81 formulations resulting
in significantly greater throat deposition compared to the
other formulations (𝑃 < 0.05, ANOVA/Tukey’s) (see Fig-
ure 1). In addition, increasing the concentration of surfactants
caused the fine particle mode (population of particles less
than ∼10 microns) to shift along the abscissa. High surfactant
concentrations (5.45% w/w) significantly dominated at cut-
off diameters ≥6.4 𝜇m (𝑃 < 0.05, ANOVA/Tukey’s), with 1%
w/w Pluronic L81 dominating between 3.99–1.36 𝜇m (𝑃 <
0.05, ANOVA/Tukey’s) (see Figure 2).
3.2. Effect of Ethanol Concentration on Particle Size Distri-
butions Emitted from HFA 227 pMDIs. A summary of the
studies for fluorescein Na labelled pMDI formulations with
varying levels of cosolvent is presented in Table 4. There was
a direct correlation between increasing ethanol concentration
resulting in enhanced particle size (VMD) and MMAD, with
significant differences noted between formulations contain-
ing 15%w/w versus 10 or 5%w/w ethanol (𝑃 < 0.05, ANOVA/
Tukey’s).
Although a decrease was noted in MMAD between
formulations containing 5 and 10% w/w EtOH, this was
not significant (𝑃 > 0.05, ANOVA/Tukey’s). Further-
more, as MMAD values increased, this corresponds to a
significantly decreased FPD between all formulations from
105.07 ± 2.31 𝜇g to 61.28 ± 1.79 𝜇g (Table 4) (𝑃 < 0.05,
ANOVA/Tukey’s). In addition, a decrease in FPF was also
noted with significant difference comparing formulations
with 15 and 13% w/w versus 10 and 5% w/w EtOH (𝑃 <
0.05, ANOVA/Tukey’s). However, there was no significant
difference in emitted doses between the formulations (𝑃 >
0.05, ANOVA/Tukey’s).These observations are not surprising
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Table 4: Comparison of HFA 227 formulations with different concentrations of ethanol (data represent mean ± SD, 𝑛 = 3).
Ethanol concentration (% w/w)/(vapor pressure, psi)
5 (59.8 psi) 10 (54.6 psi) 13 (52.8 psi) 15 (50.2 psi)
ED (𝜇g) 195.08 ± 23.25 194.26 ± 14.19 193.31 ± 12.44 209.52 ± 11.02
FPF (%) 54.31 ± 5.65 45.39 ± 2.90 35.02 ± 2.26∗∗ 29.27 ± 0.77∗
FPD (𝜇g) 105.07 ± 2.31± 87.91 ± 1.73± 67.52 ± 0.38± 61.28 ± 1.79±
MMAD (𝜇m) 5.13 ± 0.23 5.05 ± 0.15 5.55 ± 0.18 5.79 ± 0.05∗
GSD 1.74 ± 0.12 2.07 ± 0.01 1.73 ± 0.03 1.78 ± 0.01
VMD (𝜇m) 5.32 ± 0.54 8.03 ± 0.36 9.72 ± 0.56 12.0 ± 0.44∗
ED: emitted dose, MMAD: mass median aerodynamic diameter, FPF: fine particle fraction, FPD: fine particle dose, and GSD: geometric standard deviation.
∗
𝑃 < 0.05 (ANOVA/Tukey’s) 15% w/w EtOH versus 10 and 5% w/w EtOH, ∗∗𝑃 < 0.05 (ANOVA/Tukey’s) 13% w/w EtOH versus 10 and 5% w/w EtOH, and
±
𝑃 < 0.05 comparing all formulations (ANOVA/Tukey’s).
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Figure 2: Comparison of HFA227 formulations in terms of drug
deposited on each stage of Next Generation Impactor, maintaining
constant concentration of ethanol (data represent mean ± SD, 𝑛 =
3). MOC: microorifice collector. ∗𝑃 < 0.05 (ANOVA/Tukey’s)
5.45% w/w Pluronic L81 versus 0 and 1.22% w/w Pluronic L81,
∗∗
𝑃 < 0.05 (ANOVA/Tukey’s) comparing all formulations, $𝑃 <
0.05 (ANOVA/Tukey’s) 1% w/w Pluronic L81 versus 0 and 5% w/w
Pluronic L81, and #𝑃 < 0.05 (ANOVA/Tukey’s) 0%w/wPluronic L81
versus 1.22 and 5% w/w Pluronic L81.
and are consistent with our previous studies conducted using
HFA 134a propellants [11]. Thus, as expected with increased
particle size, the USP induction port (throat) deposition
also increased with increasing ethanol concentrations (see
Figure 3). Furthermore, increasing ethanol concentrations
in the HFA 227 formulations caused similar changes to the
particle size distributions (see Figure 4). Generally, the lower
ethanol concentrations (5 and 10% w/w), the greater the
mass of drug deposited at cut-off-diameters 6.4 to 0.83𝜇m
(𝑃 < 0.05, ANOVA/Tukey’s). Importantly, the positions
of the particle size modes were not changed as ethanol
concentrations are changed, rather their magnitudes were
altered. These observations are in contrast to those discussed
previously whenwe varied the surfactant concentrationwhile
keeping ethanol concentrations constant.
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Figure 3: Comparison of HFA 227 formulations in terms of drug
deposited in USP throat of NGImaintaining constant concentration
of fluorescein Na and Pluronic L81 (data represent mean ± SD, 𝑛 =
3). ∗𝑃 < 0.05 (ANOVA/Tukey’s) 15% w/w EtOH versus 10 & 5%w/w
EtOH, ∗∗𝑃 < 0.05 (ANOVA/Tukey’s) 13%w/w EtOH versus 5%w/w
EtOH.
4. Discussion
This study investigated the effects of ethanol and surfactant
(Pluronic L81) concentrations on drug particle size distri-
bution and in vitro drug aerosol deposition using pMDIs
containing propellant HFA 227. For solution-based pMDIs,
these two excipient classes are common and often necessary
for ensuring solubility and performance. Some previous
studies have developed predictive models for solution-based
formulations [15], but in general, these approaches have been
to predict MMAD or fine particle fractions. Due to the
dependency of pharmacokinetics and pharmacodynamics of
inhaled products on deposition patterns, particularly in the
challenging cases of matching performance, it may be more
useful to match whole distributions rather than measures of
central tendency or respirability.
Although pluronics are not currently used in marketed
pMDI products, several recent patents and publications have
detailed the use of these surfactants in this manner [16–19].
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Figure 4: The influence of ethanol cosolvent concentrations on the
aerodynamic particle size characteristics of HFA 227 formulations
as quantified using a Next Generation Impactor. Surfactant concen-
trations were kept constant (data represent mean ± SD, 𝑛 = 3).
MOC: microorifice collector. ∗𝑃 < 0.05 (ANOVA/Tukey’s) 15% w/w
EtOH versus 10 and 5% w/w EtOH and ∗∗𝑃 < 0.05 comparing all
formulations.
The main motivation for this work was to determine if the in
vitro aerosol performance of these model systems could be
adequately modulated using the two components mentioned
previously. Several literature reports confirm that increasing
either cosolvent or surfactant concentrations resulted in
increased emitted particle sizes. We observed that ethanol
and the Pluronic L81 surfactant caused very different effects
on the emitted particle size distributions when their concen-
trations were altered. This was significant for several reasons.
Firstly, it appears that the mechanisms by which droplet sizes
were influenced by cosolvent versus surfactants were very
different. Differing mechanisms would indicate that particle
size could be manipulated independently using these two
approaches. Furthermore, modulating drug particle size is
important for either optimizing the performance of these
products or matching the performance of products to those
already approved by regulatory agencies across the world.
Secondly, the pathway to regulatory approval of products
(generic or otherwise) appears to focus on stage-by-stage
deposition rather than mean or median values that are less
sensitive markers of deposition.Therefore, the focus of many
studies and literature reports has been MMAD and FPD
and the ability to manipulate particle size distribution for
lung targeting. This is considered an important aspect of
formulation as the Food andDrugAdministration (FDA) and
other regulatory agencies are interested in cascade impactor
stage-by-stage in vitro correlation. In this study, consistent
with several previous investigations, we showed that vary-
ing concentrations of cosolvent (ethanol) and surfactant
(Pluronic L81) caused differences in aerosol particle sizes.
Perhaps the most challenging aspect in reformulating
pMDIs, with surfactants traditionally employed in CFC-
based pMDIs and found in FDA-approved products, is the
limited solubility in the more polar HFAs [7, 20]. Sur-
factants are generally required in solution and dispersion
formulations as solubilising/dispersing agents and as valve
lubricants [5]. Cosolvents are generally required in HFA-
based formulations to aid in the solubilisation of surfactants
[5] which could affect the vapor pressure of pMDI mixtures
and thus the aerosol respirable fraction. The development
of novel surfactants for HFA-based pMDIs has been limited
but several groups focusing on this task using suspension
based pMDIs [21], and recently pluronic copolymers have
been investigated as potential surfactants in solution based
pMDI formulations by Ridder et al. [22] who used Pluronic
L81 surfactant and found good solubility in HFA 227.
As Pluronic L81 concentrations were increased, a pop-
ulation modal shift to higher particle sizes was observed.
The elevated MMAD and VMD values associated with
higher concentrations of Pluronic L81 may be attributed to
strong hydrogen bonding between Pluronic L81 and HFA
227 and the surface active nature of Pluronic L81 resulting
in decreased evaporation rates from droplet surfaces [8,
23]. Similar to cosolvent effects, another explanation is
the decreased propellant fraction leading to reduced vapor
pressures and reduction of atomization energy at the nozzle
[8]. Consequently, the increase in MMAD and VMD with
increasing Pluronic L81 concentration from 1.22 to 5.45%w/w
resulted in a greater deposition of drug in the throat, reduced
the fraction of emitted dose with 𝑑ae ≤ 4.6 𝜇m, and hence
reduced FPF and FPD.However, there appear to be important
differences in the mechanism of particle size modulation
between ethanol and Pluronic L81 (see Figures 2 and 4). It can
be seen that the effects of increasing surfactant concentration
are somewhat different from those patterns observed with
cosolvents which had the effect of moving the particle size
distributions along the ordinate axis and not the abscissa.
Considerable work on solution formulations has been
reported by several groups including Stein et al. from 3M
[24–28]. The correlation of increasing cosolvent concentra-
tions resulting in enhanced particle sizes has been attributed
to the reduced energy available for atomization due to the
decreased vapor pressures [11] and increased droplet sizes
owing to either slow or incomplete evaporation [29] at
these time scales. These studies show that ethanol caused a
decrease in the relative proportion of fine particles due to
the decrease in vapor pressure of the solution as we add
ethanol. The amount of fine particles in the aerosol cloud
is directly proportional to the square root of the pressure—
as ethanol concentration increases, the vapor pressure of the
solution decreases; hence, the number of fine particles also
decreases. This was supported by the observation of greater
drug deposition in the USP induction port for formulations
of higher ethanol content in our investigations. Moreover,
the laser diffraction data (obtained before significant evap-
oration could occur) appears to support this theory, showing
much higher particle sizes than those obtained from cascade
impaction studies [26, 30, 31].
With these differences in mind, we hypothesize that the
particle size “fingerprint” for HFA solution formulations may
be unique to the excipient selection and relative concentra-
tions. If the mechanisms by which particle size distributions
are modulated by cosolvents and surfactants are independent
of each other, a design space may be generated for each
6 BioMed Research International
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Figure 5: Concept of the design window illustrated for solution-
based HFAs containing cosolvent (changing amplitude of the par-
ticle size mode, vertical tuning) and surfactants (changing location
of the mode, horizontal tuning) in which particle size modulation
may be achieved by manipulation of these two components that act
through independent mechanisms to effect particle size change.
system (see Figure 5). In terms of reformulation efforts
and development of equivalent generic pMDIs, this type of
approach could be used to match the stage-by-stage analysis
or particle size fingerprint more rapidly. Studies in our labs
are currently underway to thoroughly test these hypotheses
using surface response analysis.
5. Conclusion
The purpose of these studies was to understand cosolvent
and surfactant contributions to particle size distributions
emitted from solution metered dose inhalers based on the
propellant HFA 227. These studies build on several pre-
vious published investigations using the propellant HFA
134a. Here, for the first time, we describe how particle size
distributions can bemodulated differently using two different
formulation excipients by shifting size distribution modes to
different locations and by modifying the amplitude of the
modes. The practical implications of using these excipients
to independently modulate particle size distributions are
that a formulation window can be generated from which
reformulation or bioequivalence research and development
can be facilitated.
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